Xolair 300 MG/2 ML syringe 2ML
Ended Awarded Last action
- Contract number
- SPE2DR26FKKL9
- Awardee
-
DMS Pharmaceutical Group Inc. UEI PX72BSBQTKJ3
- Awarding agency
-
Defense Logistics Agency
Department of Defense
- Obligated
- $18,893
Award facts
- Contract value 100% obligated
- $18,893.20 Current and potential, with all options
- Completion date 100% complete
- Current and potential, with all options
- NAICS code
- 424210 Drugs and Druggists' Sundries Merchant Wholesalers
- PSC
- 6505 Drugs And Biologicals
- Set-aside
- No set-aside
- Competition
- Full and Open Competition Negotiated Proposal / Quote
- Pricing
- Firm Fixed Price
- Place of performance
- Park Ridge, IL 60068, USA
Award details come from SAM.gov/FPDS.
About this award
The Defense Logistics Agency awarded a $18,893.20 firm fixed-price delivery order to DMS Pharmaceutical Group Inc. on January 20, 2026, for the supply of Xolair 300 mg/2 ml syringes. DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler headquartered in Park Ridge, Illinois, was selected without a set-aside designation, demonstrating the company's competitive capability in unrestricted federal procurement. The delivery order is scheduled for ultimate completion on February 10, 2026, with performance to be executed from the company's Park Ridge location.
This delivery order was issued under DMS Pharmaceutical Group's single-award Indefinite Delivery Contract with the Defense Logistics Agency's Pharmaceutical Prime Vendor Global Program Generation V (PPV-G GEN V) initiative, a $499.9 billion acquisition strategy supporting Department of Defense healthcare operations globally. The PPV-G GEN V contract, awarded on November 13, 2025, with a completion date of December 31, 2036, authorizes DLA to issue delivery orders for a comprehensive range of pharmaceutical products to support recurring medical supply needs of military healthcare facilities worldwide. DMS Pharmaceutical Group's established performance across numerous delivery orders demonstrates its capability to fulfill the diverse and specialized pharmaceutical requirements of the federal military medical system.
Quick answers
Who was awarded contract SPE2DR26FKKL9?
SPE2DR26FKKL9 was awarded to DMS Pharmaceutical Group Inc. by Defense Logistics Agency (Department of Defense) on January 20, 2026.
How much is contract SPE2DR26FKKL9 worth?
The government has obligated $18,893 on SPE2DR26FKKL9.
Is contract SPE2DR26FKKL9 an order under another contract?
Yes. SPE2DR26FKKL9 is a delivery order under SPE2DR25D9367, an indefinite delivery contract.
Was contract SPE2DR26FKKL9 competed?
The extent of competition for SPE2DR26FKKL9 was full and open competition.
On GovTribe
See this award's full record
- Every transaction and funding action
- The awardee's other awards and teaming partners
- Similar awards and recompete opportunities
- Ask GovTribe AI about this award